Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/EPHA2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EPHA2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EPHA2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EPHA2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EPHA2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EPHA2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EPHA2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190547519 | Esophagus | ESCC | regulation of protein localization to membrane | 117/8552 | 175/18723 | 1.14e-08 | 2.26e-07 | 117 |
GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
GO:00435888 | Esophagus | ESCC | skin development | 163/8552 | 263/18723 | 6.48e-08 | 1.14e-06 | 163 |
GO:00219159 | Esophagus | ESCC | neural tube development | 101/8552 | 152/18723 | 1.78e-07 | 2.79e-06 | 101 |
GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
GO:190437519 | Esophagus | ESCC | regulation of protein localization to cell periphery | 85/8552 | 125/18723 | 3.63e-07 | 5.06e-06 | 85 |
GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
GO:000206420 | Esophagus | ESCC | epithelial cell development | 136/8552 | 220/18723 | 9.50e-07 | 1.21e-05 | 136 |
GO:1903076110 | Esophagus | ESCC | regulation of protein localization to plasma membrane | 72/8552 | 104/18723 | 9.74e-07 | 1.23e-05 | 72 |
GO:190547719 | Esophagus | ESCC | positive regulation of protein localization to membrane | 73/8552 | 106/18723 | 1.13e-06 | 1.40e-05 | 73 |
GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
GO:0009150111 | Esophagus | ESCC | purine ribonucleotide metabolic process | 213/8552 | 368/18723 | 1.40e-06 | 1.69e-05 | 213 |
GO:000164918 | Esophagus | ESCC | osteoblast differentiation | 140/8552 | 229/18723 | 1.63e-06 | 1.95e-05 | 140 |
GO:000257317 | Esophagus | ESCC | myeloid leukocyte differentiation | 128/8552 | 208/18723 | 2.75e-06 | 3.15e-05 | 128 |
GO:0006163111 | Esophagus | ESCC | purine nucleotide metabolic process | 226/8552 | 396/18723 | 2.81e-06 | 3.21e-05 | 226 |
GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
GO:00073698 | Esophagus | ESCC | gastrulation | 115/8552 | 185/18723 | 4.35e-06 | 4.64e-05 | 115 |
GO:002261216 | Esophagus | ESCC | gland morphogenesis | 78/8552 | 118/18723 | 5.83e-06 | 6.03e-05 | 78 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EPHA2 | SNV | Missense_Mutation | novel | c.689G>A | p.Cys230Tyr | p.C230Y | P29317 | protein_coding | deleterious(0) | benign(0.336) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EPHA2 | SNV | Missense_Mutation | rs754656950 | c.1012N>A | p.Val338Met | p.V338M | P29317 | protein_coding | tolerated(0.13) | benign(0.056) | TCGA-AR-A2LL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
EPHA2 | SNV | Missense_Mutation | | c.625G>A | p.Ala209Thr | p.A209T | P29317 | protein_coding | deleterious(0) | benign(0.142) | TCGA-BH-A0AV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
EPHA2 | SNV | Missense_Mutation | | c.2928N>G | p.Ile976Met | p.I976M | P29317 | protein_coding | deleterious_low_confidence(0.05) | probably_damaging(0.986) | TCGA-BH-A0B7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
EPHA2 | SNV | Missense_Mutation | novel | c.638N>T | p.Glu213Val | p.E213V | P29317 | protein_coding | deleterious(0) | benign(0.054) | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
EPHA2 | insertion | Nonsense_Mutation | novel | c.331_332insTTAAGGAATTGGAGGTTTAGT | p.Gly111delinsValLysGluLeuGluValTerCys | p.G111delinsVKELEV*C | P29317 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EPHA2 | insertion | Nonsense_Mutation | novel | c.690_691insTGATTTTCCACTGGGGCCTCTATAGATGACACAC | p.Val231Ter | p.V231* | P29317 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EPHA2 | insertion | Frame_Shift_Ins | novel | c.636_637insACATTTTTAGCTGT | p.Glu213ThrfsTer185 | p.E213Tfs*185 | P29317 | protein_coding | | | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
EPHA2 | deletion | Frame_Shift_Del | novel | c.2352delC | p.Ala785ProfsTer26 | p.A785Pfs*26 | P29317 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
EPHA2 | SNV | Missense_Mutation | | c.2581C>T | p.Arg861Cys | p.R861C | P29317 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | DASATINIB | DASATINIB | 20360610 |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | TOZASERTIB | TOZASERTIB | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | LITHOGLYCOCHOLATE | LITHOGLYCOCHOLATE | 23489211 |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | MLN-8054 | MLN-8054 | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | OSI-632 | OSI-632 | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565850 | | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | DS-8895 | | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | DASATINIB | DASATINIB | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | MEDI-547 | | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | N/A | | |